Sinphar Pharmaceutical CoTPE:1734 81 EV-to-FCF is 18.46 as of Jul. 10, 2026, which is 13% above its 10-year median of 16.39. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.16 (Fairly Valued). The stock has 2 warning signs investors should review. Among 330 Biotechnology companies, Sinphar Pharmaceutical Co ranks worse than 53.64% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sinphar Pharmaceutical Co's Enterprise Value is NT$7,082 Mil.
Sinphar Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$384 Mil. Therefore, Sinphar Pharmaceutical Co's EV-to-FCF for today is 18.46.
The historical rank and industry rank for Sinphar Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TPE:1734'
s EV-to-FCF Range Over the Past 10 Years
Min: -1590.45 Med: 16.39 Max: 877.54
Current: 18.46
During the past 13 years, the highest EV-to-FCF of Sinphar Pharmaceutical Co was 877.54. The lowest was -1590.45. And the median was 16.39.
TPE:1734's EV-to-FCF is ranked worse than 53.64% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs TPE:1734: 18.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinphar Pharmaceutical Co (TPE:1734) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinphar Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sinphar Pharmaceutical Co's share price for today is NT$33.10.
Sinphar Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.922.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sinphar Pharmaceutical Co EV-to-FCF Related Terms
Sinphar Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's EV-to-FCF falls into.
Sinphar Pharmaceutical Co's current Enterprise Value is NT$7,082 Mil.
Sinphar Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$384 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a EV-to-FCF of 18.46 as of Jul. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 13% above median its historical median of 16.39. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #177 out of 330 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Sinphar Pharmaceutical Co's EV-to-FCF too high?
Sinphar Pharmaceutical Co's current EV-to-FCF of 18.46 is 13% above median its 10-year median of 16.39. The Biotechnology industry median EV-to-FCF is 16.36. Sinphar Pharmaceutical Co's value of 18.46 is 12.8% above this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #177 out of 330 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #177 out of 330 companies for EV-to-FCF. This places Sinphar Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 16.36. Sinphar Pharmaceutical Co's value of 18.46 is 12.8% above this benchmark. While the company's 10-year median is 16.39 vs. the industry median of 16.36, Sinphar Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current EV-to-FCF of 18.46 is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current EV-to-FCF is 18.46, which is 13% above median its own 10-year median of 16.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.16, compared to a current price of NT$33.10 — trading 0.2% below its estimated fair value. The current EV-to-FCF is 18.46, which is 13% above median its 10-year median of 16.39 and 12.8% above the Biotechnology industry median of 16.36. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current EV-to-FCF is 18.46 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$33.10 is trading 0.2% below its estimated GF Value™ of NT$33.16.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
EV-to-FCF: 18.46 (13% above median its 10-year median of 16.39)
GF Value™: NT$33.16 vs. price of NT$33.10 (0.2% below fair value)
Industry Position: 12.8% above the Biotechnology median (#177 of 330)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
